A glycine-based tripeptide, DT-109, has shown the ability to reverse metabolic dysfunction-associated steatohepatitis (MASH) in animal models by repairing the gut-liver axis. According to a study published in The Journal of Clinical Investigation, the compound targets a specific pathway where gut bacteria produce ammonia, which damages the intestinal barrier and triggers liver inflammation.
How Does DT-109 Treat MASH?
DT-109 functions by disrupting the communication between harmful gut bacteria and the liver. Researchers at Michigan Medicine, led by senior author Eugene Chen, M.D., Ph.D., identified that the bacterium Clostridium perfringens acts as a primary driver of MASH. This bacterium produces ammonia in the gut, which erodes the digestive tract’s lining.
When this intestinal barrier is weakened, harmful microbial products leak into the bloodstream, reaching the liver and causing inflammatory immune responses, such as the hyperactivation of CD8+ T cells. According to the study, DT-109 strengthens the intestinal barrier, effectively preventing these toxins from reaching the liver. In experiments with nonhuman primates, the compound reduced both liver inflammation and the overall severity of MASH.
Can DT-109 Benefit Cardiovascular Health?
The therapeutic reach of DT-109 may extend well beyond the liver. Researchers observed that the compound also limits the formation of atherosclerosis plaques and inhibits vascular calcification in nonhuman primates. This dual-action potential makes DT-109 a significant candidate for further pharmaceutical development.
Jifeng Zhang, Ph.D., a co-author and research professor of cardiovascular medicine at the U-M Medical School, noted that while the compound acts primarily in the gastrointestinal tract, its systemic impact is substantial. By modulating the microbiota and restoring gut integrity, the drug addresses the “gut-liver axis” in a way that may provide broader systemic protection.
What Are the Next Steps for Clinical Trials?
The research team is now focused on moving DT-109 toward human clinical trials to evaluate its safety and efficacy. Because intestinal barrier dysfunction is linked to various conditions, including inflammatory bowel disease (IBD), the team suggests that the drug’s potential applications could be wide-ranging.
Elliot Tapper, M.D., Academic Director of Hepatology at Michigan Medicine, emphasized the need for new approaches. “What patients with MASH need is a safe and effective therapy capable of improving their liver and heart health,” Tapper said. The development of the compound is currently being managed by Diapin Therapeutics, which has licensed the technology from the University of Michigan.
Frequently Asked Questions
What is MASH?
MASH stands for metabolic dysfunction-associated steatohepatitis. It is a severe form of fatty liver disease that can progress to cirrhosis, liver cancer, and liver failure.
How does DT-109 differ from existing treatments?
Unlike many treatments that focus solely on the liver, DT-109 targets the gut-liver axis by repairing the intestinal barrier and reducing the systemic influx of ammonia produced by Clostridium perfringens.
Is DT-109 available for patients now?
No. DT-109 is currently in the research and development phase. Future studies are required to confirm its safety and effectiveness in human clinical trials before it can be considered a viable treatment option.
Are there conflicts of interest regarding this study?
Yes. Several authors, including Y. Eugene Chen, are inventors of the patent for DT-109. The University of Michigan has licensed the compound to Diapin Therapeutics, and the university and Chen hold an ownership interest in the company.
Have questions about emerging liver disease therapies? Share your thoughts in the comments below or subscribe to our medical research newsletter for monthly updates on clinical breakthroughs.